ClinicalTrials.gg
RecruitingNCT05669495Updated Jan 3, 2023

ANNE Vital Sign System Remote Sleep Assessment

An observational study in Alzheimer Disease, Dementia and Mild Cognitive Impairment, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Sunnybrook Health Sciences Centre · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre — 8 open to participants now, 8 under way, 1 of them phase 3. Alzheimer Disease · Sunnybrook Health Sciences Centre.

Started
2022
the only one that year
Observational
3 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, this one is the only one that started in 2022, is one of 3 observational ones, and was the 12th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

Sleep apnea is characterized by temporary pauses or stops to participant's breathing. Currently, sleep apnea is diagnosed using an in-lab sleep study, which involves spending a night in a sleep laboratory hooked up to wires on the head, chest, and legs. However, this is not feasible for many older adults. To overcome this barrier, the investigators will utilize an investigational vital signs monitor - the Advanced NeoNatal Epidermal (ANNE) Vital Sign System (Sibel Health, Evanston, IL,USA).

The primary objective of this study is to test the hypothesis that sleep apnea is associated with accelerated cognitive decline in older adults at risk for dementia. The investigators will measure sleep apnea at baseline and 12 months later and relate this to cognitive function at the same time points.

Sex-stratification will be used in analyses as appropriate. Qualitative feedback forms will be used to collect information about participant ease of use and experience with the ANNE Vital Sign System.

Read the detailed description

Over 500,000 Canadians are currently living with dementia and this is predicted to reach one million in the next two decades. With no effective cures, there is an urgent need to identify and treat causal risk factors. Sleep and circadian rhythm disruption, including sleep deprivation, sleep fragmentation, sleep apnea, and abnormal circadian rhythms, are common. In model organisms, they accelerate development of dementia-associated neuropathologies and accumulating evidence suggests that in older adults they may be associated with a greater risk of dementia and dementia-related structural brain changes.

Sleep apnea is characterized by recurrent episodes of absent (apneas) or reduced (hypopneas) airflow in sleep, accompanied by hypercarbia and hypoxemia, and terminated by arousal and resumption of normal breathing. Sleep apnea is common in adults with Alzheimer's Disease (AD) and other dementias. The prevalence of moderate sleep apnea (apnea hypopnea index (AHI) > 15) in patients with mild AD is estimated at 68% and may be higher in moderate to severe AD. Moreover, a recent meta-analysis suggested that patients with AD have a five-fold increased odds of presenting with sleep apnea than adults with normal cognition.

The overall goal of this study is to test the hypothesis that sleep apnea is associated with accelerated cognitive decline in older adults at risk for dementia. The investigators will measure sleep apnea and its cardiovascular consequences at baseline and 12 months later and relate this to cognitive function at the same time points. To achieve this, the investigators will study participants enrolled in the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CTU) and affiliated trials. The CTU is a Canada-wide study of older adults at risk for dementia, being undertaken by the Canadian Consortium on Neurodegeneration that will begin recruitment in May 2022. It, and affiliated trials, are anticipated to recruit 750 participants from May 2022-April 2024.

In clinical practice, sleep apnea is diagnosed using inpatient polysomnography. However, this is not feasible for many older adults. To overcome this barrier, the investigators will utilize an investigational vital signs monitor - the Advanced NeoNatal Epidermal (ANNE) Vital Sign System (Sibel Inc., Evanston, IL, USA).

The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, the investigators show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.

A separate 8-site Canadian in-lab study of the ANNE Vital Sign System is already underway, with participants undergoing diagnostic polysomnography per usual care or in the context of existing research projects approved by an institutional ethics board. ANNE Vital Sign System has an approved Investigational Testing Authorization (ITA) for this in-lab study (ITA application number 319430, approved December 11, 2020).

CTU recruiting sites will refer potential participants to Sunnybrook Research Institute (SRI) to obtain informed consent and then prepare shipment of ANNE Vital Sign System and instructions to participant. After study equipment and materials are shipped to and received by the participant, study staff will instruct the participant on the proper application and use of the ANNE Vital Sign System over remote video-conference. Specifically, study staff will instruct the participant to attach the two sensors of the ANNE Vital Sign System according to manufacturer recommendations. Participants will wear the sensors for 24 hours before removing it themselves at home and shipping back to Sunnybrook Research Institute. This procedure will be completed at two time points: Baseline and 12 months later.

03

Conditions studied

  • Alzheimer Disease
  • Dementia
  • Mild Cognitive Impairment
  • Sleep Apnea
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Enrolled participants in the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CTU) and affiliated trials. All participants will be individuals ages 60-85 classified as Not Dementia according to Canadian Consortium for Neurodegeneration in Aging (CCNA) criteria and classified as being at increased risk of dementia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The only inclusion criteria for this study is that participants must have consented and enrolled into a CTU affiliated study. There are no additional inclusion criteria. Individuals from CTU affiliated studies will be asked to confirm their enrollment in a CTU affiliated study as part of the process for this study.

For reference, inclusion criteria of CTU affiliated studies from which we will recruit may include, but are not limited to, the following list:

  1. Ages 60-85
  2. Sufficient proficiency in English or French
  3. Technical ability to participate in remote assessments
  4. Meets criteria for No Dementia and one of the following (according to CCNA Criteria):

    1. Cognitively Unimpaired
    2. Cognitively Unimpaired plus Subjective Cognitive Impairment
    3. Mild Cognitive Impairment (MCI)
  5. AND Classified as being at increased risk of dementia based on at least one of the following: a. First-degree family history of dementia b. Self-Reported or documented current and/or history at midlife (45-60 years) of the following risk factors: i. Hypertension ii. Hypercholesterolemia iii. > 30 kg/m2 iv. Physical Inactivity v. Insomnia vi. Vascular-metabolic risk

Exclusion criteria

Exclusion Criteria:

  1. Known nickel allergy
  2. Known cardiac implantable device
  3. Known arrhythmias
  4. Otherwise unable to use the sensors; for example, finger amputations

For reference, exclusion criteria of CTU affiliated studies from which we will recruit may include, but are not limited to, the following list:

  1. Participants who, in the opinion of the investigator, are not able to complete trial procedures remotely or adhere to the schedule of study assessments.
  2. Individuals where English or French is not sufficiently proficient for remote clinical assessment.
  3. Individuals who do not have the technical ability. Technical ability is defined as having computer and internet access; ability to send and receive emails; ability to participate in remote assessments.
  4. Individuals who have a clinical diagnosis of Dementia
  5. Clinical Dementia Rating (CDR; telephone/video-conference administration) Score of >1 or having a diagnosis of dementia based on criteria
  6. Total Score on the (MoCA; video-conference administration) \<13
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Patient registry
No

Groups and cohorts

  • No dementia, increased risk of dementia

    Meets criteria for No Dementia and one of the following (according to CCNA Criteria): 1. Cognitively Unimpaired 2. Cognitively Unimpaired plus Subjective Cognitive Impairment 3. Mild Cognitive Impairment (MCI) AND Classified as being at increased risk of dementia based on at least one of the following: 1. First-degree family history of dementia 2. Self-Reported or documented current and/or history at midlife (45-60 years) of the following risk factors: i. Hypertension ii. Hypercholesterolemia iii. Body Mass Index \> 30 kg/m2 iv. Physical Inactivity v. Insomnia vi. Vascular-metabolic risk

    Device: ANNE Vital Sign System

Interventions

  • DeviceANNE Vital Sign System

    The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.

06

What researchers measure

Primary outcomes

  1. Apnea Hypopnea Index

    Number of times per hour breathing slows or stops

    Time frame: Baseline

  2. Apnea Hypopnea Index

    Number of times per hour breathing slows or stops

    Time frame: 12-months

  3. Oxygen Desaturation Index

    Number of times per hour oxygen dips 4% or more

    Time frame: Baseline

  4. Oxygen Desaturation Index

    Number of times per hour oxygen dips 4% or more

    Time frame: 12-months

  5. Hypoxemia Burden

    integral area under the desaturation curve

    Time frame: Baseline

  6. Hypoxemia Burden

    integral area under the desaturation curve

    Time frame: 12-months

  7. Time with oxygen saturation below 90% (O2<90)

    As described in title

    Time frame: Baseline

  8. Time with oxygen saturation below 90% (O2<90)

    As described in title

    Time frame: 12-months

Secondary outcomes

  1. Sex-stratification on Apnea Hypopnea Index

    Sex-related effects on Apnea Hypopnea Index

    Time frame: Baseline

  2. Sex-stratification on Apnea Hypopnea Index

    Sex-related effects on Apnea Hypopnea Index

    Time frame: 12-months

  3. Sex-stratification on Oxygen Desaturation Index

    Sex-related effects on Oxygen Desaturation Index

    Time frame: Baseline

  4. Sex-stratification on Oxygen Desaturation Index

    Sex-related effects on Oxygen Desaturation Index

    Time frame: 12-months

  5. Sex-stratification on Hypoxemia Burden

    Sex-related effects on Hypoxemia Burden

    Time frame: Baseline

  6. Sex-stratification on Hypoxemia Burden

    Sex-related effects on Hypoxemia Burden

    Time frame: 12-months

  7. Sex-stratification on Time with oxygen saturation below 90% (O2<90)

    Sex-related effects on Time with oxygen saturation below 90% (O2\<90)

    Time frame: Baseline

  8. Sex-stratification on Time with oxygen saturation below 90% (O2<90)

    Sex-related effects on Time with oxygen saturation below 90% (O2\<90)

    Time frame: 12-months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — LORIS is a web-based database solution for neuroimaging and other research data that is physically located at McGill University in Montreal. It will store data that has been processed to remove any direct identifiers of an individual study participant. Study subjects will be assigned a unique coded study identification number (LORIS Project Study Centre ID (PSCID)) that will be used to store their data. Local study sites will be responsible for storing all participant identifying information (name, contact, e-mail address) in secured encrypted databases and to maintain the master file that links the participant to their unique LORIS PSCID.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Duration of study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Oct 2024, 23 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 23 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Jan 3, 2023
StartActual
Nov 10, 2022
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2025
Last update
Jan 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669495
Collaborators
Canadian Consortium on Neurodegeneration in Aging
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Nov 10, 2022
Primary completion
Oct 2024 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jan 3, 2023

Study contacts

Andrew Centen
Contact
andrew.centen@sunnybrook.ca
416-480-5143

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion